An observational study in Muscle Weakness, sponsored by Minia University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Minia University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Muscle Weakness with a site in Egypt — 4 open to participants now, 4 under way, none of them phase 3. Muscle Weakness · Egypt.
Among the 16 studies in Muscle Weakness with a site in Egypt, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 6th registered.
478 studies on the registry are indexed under Muscle Weakness; 72 are open to participants now.
Browse Muscle Weakness studies →4 of the 16 studies in Muscle Weakness with a site in Egypt are open now. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 50–70
Cairo University · Sites in Egypt
Ages 25–45
Cairo University · Sites in Egypt
Ages 27–40
Ahram Canadian University · Sites in Egypt
Ages 18–45 · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 52 Muscle Weakness studies recruiting now, 25 (48%) set no upper age limit and 20 (38%) stop at 75 or younger; 5 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is below the median of 66 across 107 observational studies indexed under Muscle Weakness.
Median enrollment 61 across the 9 interventional studies, 58 across the 7 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
Minia University is the lead sponsor of 374 studies on the registry; 121 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Minia University has 1 study filed under Muscle Weakness — fewer than ten, so there is no comparison to draw.
2 of the studies in Muscle Weakness with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07692126Cairo UniversityCore Stability vs Scapular Stabilization on Hand Grip Strength in Chronic Myofascial Neck Pain | 2027-01-01 |
| NCT07855341Ain Shams UniversityLow-Volume Pericapsular Nerve Group (PENG) Block With Dexamethasone vs Standard-Volume PENG Block After Total Hip Arthroplasty | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Muscle Weakness with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Intensive care unit -acquired weakness (ICU- AW) is a common consequence linked to a worse outcome as evidenced by prolonged mechanical ventilation, longer ICU stays, greater mortality rates and a lower quality of life for survivors, so early detection and treatment of ICU-AW are critical. However, there is no "gold standard" currently available for assessing and diagnosing ICU-AW. It's crucial to develop diagnostic methods that enable for early detection and risk stratification in all critically ill patients, such as:
GDF-15 (growth differentiation factor-15) is thought to be a mediator of muscle atrophy because its level increases in the muscular atrophy As a result, measuring GDF-15 seems promise for diagnosing muscle atrophy.
After obtaining the approval of research ethical committee of faculty of medicine, Minia university, written informed consent will be obtained from all participants or their legal representatives prior to study inclusion, this prospective cross sectional non randomized observational study will be conducted in intensive care unit Minia university hospital, on conscious non-mechanically ventilated patients with expected ICU stay 7 days or more. Based on inclusion and exclusion criteria, patients who met eligibility criteria, the prognosis and outcome of patients developing ICU-AW will be observed.
Parameters will be assessed:
patients older than 18, conscious non mechanically ventilated patients and those with expected ICU stay more than 7 days during the period from September 2023 to September 2024
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- unconscious patients spinal cord injury limb fracture or amputations history of cognitive dysfunction severe oedema end stage kidney disease
muscle weakness
Diagnostic Test: growth differentiation factor 15
rowth differentiation factor-15 (GDF-15) is a novel cytokine secreted by a variety of cells like macrophages, adipocytes, normally expressed in high amounts by placenta
Also known as: urea to creatinine ratio
Incidence
to investigate the incidence of intensive care unit acquired muscle weakness
Time frame: 1 year
Disease relations
to examine if there is any correlation between GDF15 level or urea-creatinine ratio and ICU acquired muscle weakness
Time frame: 1 year
Daily activity and mortality
to investigate the influence of muscle weakness on daily activity and mortality of ICU acquired patients
Time frame: 1 year
Ran from Oct 2023 to primary completion in Oct 2024, 12 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Sep 2023 → Oct 2023, primary completion Sep 2024 → Oct 2024 and completion Sep 2024 → Nov 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.